Gene therapy for HIV infection

Bruce A. Bunnell, Richard A. Morgan

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

The ultimate goal of gene therapy for HIV-1 is to inhibit viral replication and the resultant AIDS pathogenesis. Gene therapy for HIV-1 requires the introduction of genes that effectively inhibit viral replication by blocking expression of viral genes or altering the normal function of HIV-1 associated proteins. This review details the various anti-HIV-1 gene therapy strategies that have been developed to effectively inhibit HIV-1 replication. The review covers three broad categories: i) gene therapy using nucleic acid moieties such as gene vaccines, antisense DNA/RNA, RNA decoys, and ribozymes; ii) protein approaches such as trans-dominant negative proteins and single chain antibodies; and iii) immunotherapy using HIV-1 specific cytotoxic T cells. The discussion focuses on the effectiveness of the various techniques in preclinical experiments and in animal models. Also, the status of all of the current RAC/FDA approved clinical protocols for anti-HIV-1 gene therapy strategies is reviewed.

Original languageEnglish
Pages (from-to)209-224
Number of pages16
JournalDrugs of Today
Volume32
Issue number3
StatePublished - 1996

Fingerprint Dive into the research topics of 'Gene therapy for HIV infection'. Together they form a unique fingerprint.

  • Cite this

    Bunnell, B. A., & Morgan, R. A. (1996). Gene therapy for HIV infection. Drugs of Today, 32(3), 209-224.